STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Aurora Spine Announces Initial Surgeries using its AERO™ Lumbar Fusion System

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags

Aurora Spine (OTCQB: ASAPF) has announced the successful completion of initial surgeries using its new AERO™ Lumbar Fusion System. The minimally invasive procedures were performed by both an orthopedic surgeon and an interventionalist on the lumbar spine region.

The AERO system, a patent-pending device cleared for use from spinal levels C2 to S1, is designed for patients with facet joint-related pain or instability. The company has 10 kits ready for future procedures and expects additional surgeons to adopt the technology in coming months. The system can be used as a standalone fusion procedure or as a complement to larger spinal fusion surgeries, targeting patients with mechanical back pain, minor instability, or degenerative joint disease who haven't responded to conservative therapies.

Loading...
Loading translation...

Positive

  • Initial surgical procedures with AERO™ Lumbar Fusion System successfully completed
  • System received regulatory clearance for broad spinal application (C2 to S1)
  • 10 surgical kits already available for future procedures
  • Strong early interest from surgeons in adopting the technology

Negative

  • None.

CARLSBAD, CALIFORNIA, July 09, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced initial surgeries using Aurora Spine’s newest product, the AERO™ Lumbar Fusion System, have commenced. The minimally invasive procedures using the AERO were conducted by two different surgeons, one ortho surgeon and one interventionalist. The initial surgeries performed were procedures done on the lumbar part of the spine.

“We are extremely pleased to announce our newest product: the AERO Lumbar Fusion System, has begun to be used by surgeons and implanted into patients,” said Trent Northcutt, President and CEO of Aurora Spine. “Initial feedback has been extremely positive, and we expect additional surgeons to start using the AERO in the coming months. Given the early interest in using this new technology, we have 10 kits available and ready for future lumbar fusion procedures. It is great to see strong interest in the AERO and I’m proud of our team with their ‘speed-to-market’ with regards to getting the AERO from development to approval to now being implanted in patients. We are proud of this achievement and excited about the AERO’s potential to become a significant growth driver for Aurora.”

The AERO MIS Lumbar Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries.

Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption—aligning with Aurora Spine’s commitment to advancing patient-first, surgeon-friendly innovations.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of proprietary, minimally invasive, and regenerative technologies. The company is committed to improving surgical outcomes through innovation, efficiency, and patient-centered design.

For more information, visit: www.aurora-spine.com

Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, many of which are beyond Aurora Spine’s control. Forward-looking statements include, but are not limited to, statements regarding the expected use and success of the Company’s products, including the AERO Facet Fusion System. Actual results may differ materially. Please refer to Aurora Spine’s final prospectus and public filings for additional information on risks and uncertainties.

These forward-looking statements speak only as of the date of this release. Aurora Spine undertakes no obligation to revise or update them to reflect future events or circumstances.

Contacts:

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004

www.aurora-spine.com

Investor Contact:

Adam Lowensteiner
Lytham Partners
(646) 829-9702
Email: asapf@lythampartners.com


FAQ

What is the AERO™ Lumbar Fusion System by Aurora Spine (ASAPF)?

The AERO™ is a patent-pending minimally invasive device designed for facet joint-related pain or instability, cleared for use from spinal levels C2 to S1. It can be used as a standalone procedure or complement to larger spinal fusion surgeries.

How many AERO™ surgical kits does Aurora Spine have available?

Aurora Spine has 10 kits available and ready for future lumbar fusion procedures.

Who performed the initial AERO™ Lumbar Fusion System surgeries?

The initial surgeries were performed by two different surgeons - one orthopedic surgeon and one interventionalist.

What types of patients is the Aurora Spine AERO™ system designed for?

The AERO™ system is designed for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who haven't responded to conservative therapies.

What spinal levels is the Aurora Spine AERO™ system cleared for?

The AERO™ Lumbar Fusion System is cleared for use from spinal levels C2 to S1 (inclusive).
Aurora Spine

OTC:ASAPF

ASAPF Rankings

ASAPF Latest News

ASAPF Stock Data

15.48M
57.17M
25.94%
0%
Medical Devices
Healthcare
Link
Canada
Toronto